BEUDAMED
    FDA Adverse Event Injury Summary report: N

    MEDTRONIC SURGICAL ANNULOPLASTY PRODUCTS

    MDR report key: 16942201 · Received May 16, 2023

    Report

    Report Number
    2025587-2023-02079
    Event Type
    Injury
    Date Received
    May 16, 2023
    Date of Event
    March 29, 2022
    Report Date
    May 16, 2023
    Manufacturer
    MEDTRONIC HEART VALVES DIVISION
    Product Code
    KRH
    PMA / PMN Number
    K061127
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Location
    IT
    Reporter Occupation
    PHYSICIAN
    Health Professional
    Yes

    Narratives

    Additional Manufacturer Narrative · 0

    CITATION: PAPARELLA D, MARGARI V, SANTARPINO G, MOSCARELLI M, GUIDA P, FATTOUCH K ET AL. COMPARISON OF A FULL STERNOTOMY WITH A MINIMALLY INVASIVE APPROACH FOR CONCOMITANT MITRAL AND TRICUSPID VALVE SURGERY. EUR J CARDIOTHORAC SURG 2022; DOI:10.1093/EJCTS/EZAC167. EARLIEST DATE OF PUBLICATION USED FOR DATE OF EVENT. MEDTRONIC ANNULOPLASTY PRODUCTS REFERENCED: CG FUTURE (PRODUCT CODE KRH, PMA# K061127), CONTOUR 3D (PRODUCT CODE KRH, PMA# K101212). EARLIEST APPROVED PRODUCT USED FOR PRODUCT CODE AND PMA#. NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. WITHOUT RETURN OF THE PRODUCT, NO DEFINITIVE CONCLUSION CAN BE MADE REGARDING THE CLINICAL OBSERVATIONS. MEDTRONIC IS SUBMITTING THIS REPORT TO COMPLY WITH FDA REPORTING REGULATIONS UNDER 21 CFR PARTS 4 AND 803. THIS REPORT IS BASED UPON INFORMATION OBTAINED BY MEDTRONIC, WHICH THE COMPANY MAY NOT HAVE BEEN ABLE TO FULLY INVESTIGATE OR VERIFY PRIOR TO THE DATE THE REPORT WAS REQUIRED BY THE FDA. MEDTRONIC HAS MADE REASONABLE EFFORTS TO OBTAIN MORE COMPLETE INFORMATION AND HAS PROVIDED AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. IN PARTICULAR, THIS REPORT DOES NOT CONSTITUTE AN ADMISSION BY ANYONE THAT THE PRODUCT DESCRIBED IN THIS REPORT HAS ANY ¿DEFECTS¿ OR HAS ¿MALFUNCTIONED¿. THESE WORDS ARE INCLUDED IN THE FDA 3500A FORM AND ARE FIXED ITEMS FOR SELECTION CREATED BY THE FDA TO CATEGORIZE THE TYPE OF EVENT SOLELY FOR THE PURPOSE OF REGULATORY REPORTING. MEDTRONIC OBJECTS TO THE USE OF THESE WORDS AND OTHERS LIKE THEM BECAUSE OF THE LACK OF DEFINITION AND THE CONNOTATIONS IMPLIED BY THESE TERMS. THIS STATEMENT SHOULD BE INCLUDED WITH ANY INFORMATION OR REPORT DISCLOSED TO THE PUBLIC UNDER THE FREEDOM OF INFORMATION ACT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. A GOOD FAITH EFFORT WILL BE MADE TO OBTAIN THE APPLICABLE INFORMATION RELEVANT TO THE REPORT. IF INFORMATION IS PROVIDED IN THE FUTURE, A SUPPLEMENTAL REPORT WILL BE ISSUED.

    Description of Event or Problem · 0

    LITERATURE WAS REVIEWED REGARDING THE OUTCOMES OF PATIENTS UNDERGOING CONCOMITANT MITRAL AND TRICUSPID VALVE SURGERY EITHER WITH A STANDARD FULL STERNOTOMY OR A MINIMALLY INVASIVE APPROACH. A TOTAL OF 1,048 PATIENTS WERE INCLUDED IN THE STUDY. MEDTRONIC (CG FUTURE AND CONTOUR 3D ANNULOPLASTY RINGS, HANCOCK II AND MOSAIC BIOPROSTHETIC VALVES) AND NON-MEDTRONIC (LIVANOVA, CARBOMEDICS, EDWARDS, W. H. GORE) DEVICES WERE USED IN THE STUDY. THE AUTHORS OBSERVED 48 DEATHS WITHIN 30 DAYS OF VALVE SURGERY. NO EVIDENCE WAS PRESENTED TO SUGGEST THAT A MEDTRONIC DEVICE OR ITS FUNCTION CONTRIBUTED TO ANY OF THE DEATHS. OTHER ADVERSE EVENTS THAT OCCURRED WERE DESCRIBED AS FOLLOWS: BLOOD TRANSFUSION, ACUTE KIDNEY INJURY, ATRIAL FIBRILLATION, PERMANENT PACEMAKER INSERTION, WOUND INFECTION, REOPENING FOR BLEEDING/COMPLICATIONS, PULMONARY COMPLICATION/REINTUBATION, TRACHEOSTOMY, CONFUSION/DELIRIUM, STROKE, LOW CARDIAC OUTPUT (INTRA-AORTIC BALLOON PUMP AND/OR INOTROPIC USE FOR MORE THAN 2 DAYS), MODERATE MITRAL REGURGITATION, MODERATE TRICUSPID REGURGITATION, SEPSIS, AND CARDIAC ARREST. NO ADDITIONAL ADVERSE PATIENT EFFECTS WERE NOTED.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    1894016 MEDTRONIC SURGICAL ANNULOPLASTY PRODUCTS RING, ANNULOPLASTY KRH MEDTRONIC HEART VALVES DIVISION MDT-ANNULOPLASTY

    Patients

    Seq Age Sex Outcome Treatment
    1 72 YR Female Required Intervention| L